Abstract
Monoclonal antibodies have been developed to optimize treatment effects in various malignant and nonmalignant conditions, by selectively targeting key components of the underlying pathophysiologic processes. Rituximab, a chimeric anti-CD20 antibody has revolutionized treatment of malignant lymphomas, extending remission rates, diseasefree survival and overall survival, all achieved with minimal toxicity. Bevacizumab, a humanized monoclonal antiantibody with anti-angiogenetic properties through inhibition of vascular endothelial growth factor, was initially approved for the adjuvant treatment of metastatic colorectal cancer with promising results. Eculizumab, a selective inhibitor of the complement terminal cascade, was the first etiologic treatment of intravascular hemolysis in patients with the rare, acquired paroxysmal nocturnal hemoglobinuria (PNH). Although none of these agents has direct antithrombotic properties, there is increasing evidence of their preemptive and therapeutic use in rare acquired thrombotic disorders, including thrombotic thrombocytopenic purpura (TTP), central retinal vein occlusion (CRVO) and PNH-associated thrombophilia. This brief review aims to discuss hopes and pitfalls of these new approaches in the context of the underlying mechanisms that lead to thrombosis in these disorders.
Keywords: Thrombosis, eculizumab, rituximab, bevacizumab, retinal vein, paroxysmal nocturnal hemoglobinuria, thrombotic thrombocytopenic purpura
Current Vascular Pharmacology
Title: Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion
Volume: 8 Issue: 1
Author(s): Panayiotis D. Ziakas, Petros Kopterides and Michael Voulgarelis
Affiliation:
Keywords: Thrombosis, eculizumab, rituximab, bevacizumab, retinal vein, paroxysmal nocturnal hemoglobinuria, thrombotic thrombocytopenic purpura
Abstract: Monoclonal antibodies have been developed to optimize treatment effects in various malignant and nonmalignant conditions, by selectively targeting key components of the underlying pathophysiologic processes. Rituximab, a chimeric anti-CD20 antibody has revolutionized treatment of malignant lymphomas, extending remission rates, diseasefree survival and overall survival, all achieved with minimal toxicity. Bevacizumab, a humanized monoclonal antiantibody with anti-angiogenetic properties through inhibition of vascular endothelial growth factor, was initially approved for the adjuvant treatment of metastatic colorectal cancer with promising results. Eculizumab, a selective inhibitor of the complement terminal cascade, was the first etiologic treatment of intravascular hemolysis in patients with the rare, acquired paroxysmal nocturnal hemoglobinuria (PNH). Although none of these agents has direct antithrombotic properties, there is increasing evidence of their preemptive and therapeutic use in rare acquired thrombotic disorders, including thrombotic thrombocytopenic purpura (TTP), central retinal vein occlusion (CRVO) and PNH-associated thrombophilia. This brief review aims to discuss hopes and pitfalls of these new approaches in the context of the underlying mechanisms that lead to thrombosis in these disorders.
Export Options
About this article
Cite this article as:
Ziakas D. Panayiotis, Kopterides Petros and Voulgarelis Michael, Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion, Current Vascular Pharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157016110790226651
DOI https://dx.doi.org/10.2174/157016110790226651 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intravitreal Bevacizumab for Diabetic Retinopathy
Current Diabetes Reviews Diffuse Correlation Spectroscopy (DCS): A Diagnostic Tool for Assessing Tissue Blood Flow in Vascular-Related Diseases and Therapies
Current Medical Imaging Subthreshold Diode Micropulse Laser Photocoagulation (SDM) as Invisible Retinal Phototherapy for Diabetic Macular Edema: A Review
Current Diabetes Reviews Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews The Impact of Oxidative Stress on Islet Transplantation and Monitoring the Graft Survival by Non-Invasive Imaging
Current Medicinal Chemistry Pharmacological Benefits of Active Components of Natural Products Against Traumatic Brain Injury - A Review
Current Pharmacogenomics and Personalized Medicine Neovascular Age-related Macular Degeneration: Past, Present, and Future
Current Angiogenesis (Discontinued) Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets Recent Patents on Cardiovascular Stem Cells
Recent Patents on Cardiovascular Drug Discovery Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Anti-VEGF Treatment in Corneal Diseases
Current Drug Targets Pharmacogenomics of Open-Angle Glaucoma
Current Pharmacogenomics and Personalized Medicine Pathophysiology of the Vascular Wall and its Relevance for Cerebrovascular Disorders in Aged Rodents
Current Neurovascular Research Novel and Emerging Targeted Therapies of Colorectal Cancer
Current Clinical Pharmacology Proteomic Analysis of the Vitreous Body in Proliferative and Non-Proliferative Diabetic Retinopathy
Current Proteomics Triamcinolone Acetonide and Bevacizumab Induced Raised Intraocular Pressure in An Elderly Male Diabetic Patient - A Case Report
Current Drug Safety Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Controversies in Pharmacological Treatment of Inflammatory Component of Macular Edema
Current Pharmaceutical Design Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Mini-Reviews in Medicinal Chemistry